Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 16, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study aims to investigate the long-term effectiveness and safety of the rituximab biosimilar CT-P10 (Truxima) in combination with cyclophosphamide (Cytoxan), vincristine (Oncovin), and prednisone (Deltasone) (CVP) compared with rituximab (Rituxan) for the treatment of advanced-stage follicular lymphoma (FL). The study concluded that the overall safety and long-term effectiveness of CT-P10 are similar to rituximab for the treatment of FL.

Some background

Follicular lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma (NHL). It arises from B-cell lymphocytes, a type of white blood cell. Rituximab, a CD-20 antibody in combination with CVP chemotherapy is a preferred first-line therapy for treatment of advanced FL.

CT-P10 is a rituximab biosimilar that has been approved by the FDA for its similarity in effectiveness for FL treatment. A biosimilar drug is very close in structure and function to the original drug. It is usually significantly cheaper compared to the original drug. The substantial cost savings allows CT-P10 wide access to patients.

However, the long-term effectiveness and safety for CT-P10 in comparison to rituximab in patients with advanced FL are still unknown.

Methods & findings

This study involved 140 patients with advanced FL. Patients were randomly assigned to receive either rituximab with CVP (70; group 1) or CT-P10 with CVP (70; group 2). The average follow-up period was 39.9 months. 

After 4 years, 55% in group 1 and 61% o in group 2 were alive without cancer worsening. Overall survival rates after 4 years were 93% for group 1 and 88% for group 2.

90% of patients in group 2 and 86% in group 1 experienced side effects related to treatment. Infusion related reactions and low white blood cells were the most common side effects in both groups. 

The bottom line

The study concluded that the long-term effectiveness and safety for CT-P10 with CVP were similar to rituximab and CVP for patients with advanced FL.

The fine print

The study was supported and funded by Celltrion, the manufacturer of CT-P10.

Published By :

Blood advances

Date :

Sep 14, 2021

Original Title :

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.

click here to get personalized updates